07 — Mitochondrial dysfunction
"Antagonistic" hallmark (López-Otín et al., Cell 2023, doi:10.1016/j.cell.2022.11.001). In plain terms: mitochondria are the "power plants" of the cell. With age, they produce less energy, leak more toxic waste, and the cell is worse at recycling worn-out plants.
1. Definition
Mitochondria make ATP (the cell's "energy currency") through the respiratory chain. They also regulate calcium, cell death and part of cell signalling. With age, their efficiency falls, their own DNA (mtDNA) accumulates mutations, quality control (mitophagy, formation of new mitochondria) weakens and NAD+ declines. The hallmark is called "antagonistic" because at low doses, mitochondrial by-products (reactive oxygen species, ROS) are useful signals; it is their chronic excess that becomes harmful (Sun 2016, doi:10.1016/j.molcel.2016.01.028).
2. Mechanisms and sources
Mitochondrial DNA mutations. mtDNA (37 genes) is copied often and poorly protected. "Mutator" mice, whose mitochondrial DNA polymerase proofreads its copies poorly (POLG), accumulate mutations and age prematurely: hair loss, osteoporosis, anaemia, shortened lifespan (Trifunovic 2004, doi:10.1038/nature02517). This aging works mainly through cell death (apoptosis), not through excess oxidative stress (Kujoth 2005, doi:10.1126/science.1112125). In older humans, mutations are distributed as a "mosaic": some muscle fibres or neurons lose their respiratory chain and others do not (Kauppila 2017, doi:10.1016/j.cmet.2016.09.017).
The free radical theory scaled back. The old idea ("ROS damage everything, so antioxidants extend life") is largely refuted:
- low-dose ROS trigger useful defences (mitohormesis). Taking vitamins C and E suppresses the metabolic benefits of exercise (Ristow 2009, doi:10.1073/pnas.0903485106);
- a Cochrane meta-analysis of 78 trials concludes that high-dose beta-carotene, vitamin E and vitamin A slightly increase mortality (Bjelakovic 2012, doi:10.1002/14651858.CD007176.pub2).
NAD+ decline. NAD+ is essential to the respiratory chain and to sirtuins (hallmark 06). It falls with age in several tissues, partly because the enzyme CD38, carried by inflammatory immune cells, consumes more of it (Camacho-Pereira 2016, doi:10.1016/j.cmet.2016.05.006; review: Covarrubias 2021, doi:10.1038/s41580-020-00313-x).
Failing quality control. The cell normally removes worn-out mitochondria (mitophagy, the PINK1/Parkin pathway, whose mutations cause familial forms of Parkinson's disease: Pickrell 2015, doi:10.1016/j.neuron.2014.12.007) and makes new ones (biogenesis, via PGC-1α). Both processes decline with age.
Leaks and inflammation. A damaged mitochondrion can release its DNA into the cell. The immune system then mistakes it for a virus and triggers an interferon response via cGAS-STING (West 2015, doi:10.1038/nature14156). This is a direct bridge to chronic inflammation.
Sources: sedentary lifestyle (the leading modifiable factor), overeating, drugs toxic to mitochondria, inherited mtDNA mutations.
3. Symptoms and clinical manifestations
- Muscle: the oxidative capacity of muscle falls by about 8 % per decade in humans, with less mtDNA and fewer mitochondrial proteins (Short 2005, doi:10.1073/pnas.0501559102). This contributes to fatigue, sarcopenia and exercise intolerance.
- Brain: Parkinson's disease (PINK1, Parkin); debated contribution to Alzheimer's.
- Heart and vessels: heart failure, endothelial dysfunction.
- Metabolism: insulin resistance, fatty liver.
- Primary mitochondrial diseases (rare, genetic in origin): myopathies, Barth syndrome, MELAS. They serve as "accelerated models" and led to the first approval of a drug targeting mitochondria (see §5).
4. Interactions with the other hallmarks
- Cellular senescence (08): failing mitochondria are enough to induce senescence with a particular SASP, driven by the NAD+/NADH ratio (Wiley 2016, doi:10.1016/j.cmet.2015.11.011). Conversely, removing the mitochondria from a senescent cell erases a large part of its phenotype (Correia-Melo 2016, doi:10.15252/embj.201592862). Review: Miwa 2022, doi:10.1172/JCI158447.
- Chronic inflammation (11): released mtDNA activates cGAS-STING (West 2015) and the NLRP3 inflammasome.
- Deregulated nutrient sensing (06): AMPK, sirtuins and PGC-1α link available energy to mitochondrial biogenesis; shared NAD+.
- Disabled macroautophagy (05): mitophagy is a form of autophagy; its decline lets worn-out mitochondria accumulate.
- Genomic instability (01): mtDNA mutations are part of genomic instability; ROS also damage nuclear DNA.
- Epigenetic alterations (03): intermediates of mitochondrial metabolism (acetyl-CoA, α-ketoglutarate, NAD+) feed the enzymes of the epigenome.
- Stem cell exhaustion (09): in mice, restoring NAD+ revives the mitochondrial function of muscle stem cells and slightly extends life (Zhang 2016, doi:10.1126/science.aaf2693).
- Loss of proteostasis (04): mitochondrial unfolded protein response (UPRmt).
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Endurance and interval exercise | Biogenesis (PGC-1α), mitophagy | Human trials (RCT); recommendation | High-intensity interval training increases the mitochondrial capacity of old muscle and protein synthesis | Robinson 2017, doi:10.1016/j.cmet.2017.02.009 |
| Urolithin A | Mitophagy | Preclinical, then human phase 2 trials | Worm: extends life; mouse: improves muscle (Ryu 2016). Human: safe, improved mitochondrial signature (Andreux 2019); muscle endurance and biomarkers improved at 4 months in 65-90-year-olds (Liu 2022) and in overweight 40-64-year-olds (Singh 2022) | Ryu 2016, doi:10.1038/nm.4132; Andreux 2019, doi:10.1038/s42255-019-0073-4; Liu 2022, doi:10.1001/jamanetworkopen.2021.44279; Singh 2022, doi:10.1016/j.xcrm.2022.100633 |
| Nicotinamide riboside (NR) | NAD+ | Human phase 1-2 trials | Well tolerated, blood NAD+ increased (Martens 2018); in old muscle, the NAD+ metabolome rises and inflammatory signals fall, with no bioenergetic gain (Elhassan 2019) | Martens 2018, doi:10.1038/s41467-018-03421-7; Elhassan 2019, doi:10.1016/j.celrep.2019.07.043 |
| Nicotinamide mononucleotide (NMN) | NAD+ | Preclinical; human phase 2 trial (n=25) | Mouse: mitigates physiological decline (Mills 2016). Prediabetic women: improved muscle insulin sensitivity (Yoshino 2021) | Mills 2016, doi:10.1016/j.cmet.2016.09.013; Yoshino 2021, doi:10.1126/science.abe9985 |
| NAD+ precursor in old mice | Stem cells | Preclinical | Stem cell function restored, life slightly extended | Zhang 2016, doi:10.1126/science.aaf2693 |
| MitoQ (mitochondria-targeted antioxidant) | Mitochondrial ROS | Human trial (crossover RCT, n=20) | Improved vascular function in 60-79-year-olds | Rossman 2018, doi:10.1161/HYPERTENSIONAHA.117.10787 |
| Elamipretide (SS-31, Forzinity) | Cardiolipin (inner membrane) | Approved (FDA accelerated approval, 19 Sept. 2025) for Barth syndrome, on muscle strength (intermediate endpoint); confirmatory trial required | First approved drug that targets mitochondria; no aging-related indication | FDA, https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome |
| Classic antioxidants (vitamins A, E, beta-carotene) | Global ROS | Meta-analysis of RCTs | No benefit; slightly increased mortality; hinder adaptation to exercise | Bjelakovic 2012, doi:10.1002/14651858.CD007176.pub2; Ristow 2009, doi:10.1073/pnas.0903485106 |
| CD38 inhibition | NAD+ consumption | Preclinical | Maintains NAD+ and mitochondrial function in old mice | Camacho-Pereira 2016, doi:10.1016/j.cmet.2016.05.006 |
6. Open questions
- Is NAD+ really limiting in humans? Precursors do raise NAD+ in the blood, but functional gains are slim or absent. It is not yet known which tissues benefit.
- Cause or consequence? In humans, mitochondrial decline largely reflects the decline in physical activity. It remains hard to separate "intrinsic" aging from a sedentary lifestyle.
- mtDNA mosaicism: must a threshold of failing cells be reached for a tissue to suffer? How can it be measured in a living person?
- Which ROS should be reduced, where and when? Targeted antioxidants (MitoQ, SkQ1) remain to be validated on solid clinical endpoints.
- Mitophagy: does urolithin A really act through mitophagy in humans? Direct measurements in tissue are missing.
- Biomarkers: there is still no standard, accessible measure of mitochondrial health (phosphorus spectroscopy, respirometry on biopsy, mtDNA in blood).
Note: a frequently cited study on PINK1/Parkin and STING inflammation (Sliter 2018, Nature) was retracted; it is not used here.
7. References
- López-Otín C et al. Hallmarks of aging: An expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
- Sun N, Youle RJ, Finkel T. The mitochondrial basis of aging. Mol Cell 2016. doi:10.1016/j.molcel.2016.01.028
- Trifunovic A et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004. doi:10.1038/nature02517
- Kujoth GC et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005. doi:10.1126/science.1112125
- Kauppila TES et al. Mammalian mitochondria and aging: an update. Cell Metab 2017. doi:10.1016/j.cmet.2016.09.017
- Ristow M et al. Antioxidants prevent health-promoting effects of physical exercise in humans. PNAS 2009. doi:10.1073/pnas.0903485106
- Bjelakovic G et al. Antioxidant supplements for prevention of mortality… Cochrane Database Syst Rev 2012. doi:10.1002/14651858.CD007176.pub2
- Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction… Cell Metab 2016. doi:10.1016/j.cmet.2016.05.006
- Covarrubias AJ et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021. doi:10.1038/s41580-020-00313-x
- Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 2015. doi:10.1016/j.neuron.2014.12.007
- West AP et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 2015. doi:10.1038/nature14156
- Short KR et al. Decline in skeletal muscle mitochondrial function with aging in humans. PNAS 2005. doi:10.1073/pnas.0501559102
- Wiley CD et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab 2016. doi:10.1016/j.cmet.2015.11.011
- Correia-Melo C et al. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J 2016. doi:10.15252/embj.201592862
- Miwa S et al. Mitochondrial dysfunction in cell senescence and aging. J Clin Invest 2022. doi:10.1172/JCI158447
- Zhang H et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 2016. doi:10.1126/science.aaf2693
- Robinson MM et al. Enhanced protein translation underlies improved metabolic and physical adaptations to different exercise training modes in young and old humans. Cell Metab 2017. doi:10.1016/j.cmet.2017.02.009
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans… Nat Med 2016. doi:10.1038/nm.4132
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019. doi:10.1038/s42255-019-0073-4
- Liu S et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Netw Open 2022. doi:10.1001/jamanetworkopen.2021.44279
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health… Cell Rep Med 2022. doi:10.1016/j.xcrm.2022.100633
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018. doi:10.1038/s41467-018-03421-7
- Elhassan YS et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome… Cell Rep 2019. doi:10.1016/j.celrep.2019.07.043
- Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab 2016. doi:10.1016/j.cmet.2016.09.013
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021. doi:10.1126/science.abe9985
- Rossman MJ et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension 2018. doi:10.1161/HYPERTENSIONAHA.117.10787
- FDA. FDA grants accelerated approval to first treatment for Barth syndrome (elamipretide), 19 Sept. 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome